By The U.S. Food and Drug Administration approved the combination of tremelimumab (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer with no sensitizing epidermal growth factor receptor mutation or anaplastic lymphoma kinase genomic tumor aberrations.
FDA approves drug combo for metastatic non-small cell lung cancer
Specialist researcher holding microscope slide analyzing blood sample working at coronavirus vaccine development during virus examination in microbiology hospital laboratory. Biochemistry experiment
Comments